1. #P87: “Results of Epigenetic-Based Quantitative PCR Assisted Immune Cell Counting Analysis in Bavituximab SUNRISE Trial Subgroup” https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring Nikoletta L. Kallinteris 1, Thomas O. Kleen 2, Min Tang 1, Shen Yin 1, Tobi Guennel 3, Jennifer Lai 1, Victor Nowakowski 2, Steven Olek 2, Steve King 1, Joseph S. Shan 1 1 Peregrine Pharmaceuticals 2 Epiontis GmbH, Berlin, Germany 3 Precision Medicine, Frederick MD SITC’17 #P87 ABSTRACT: BACKGROUND SUNRISE (NCT01999673 https://www.clinicaltrials.gov/ct2/show/NCT01999673 ), a global, double-blind, randomized Phase III trial of docetaxel bavituximab (D+B) or docetaxel+placebo (D+P) in previously treated non-squamous NSCLC, demonstrated similar OS in the intent-to-treat population (n=597). In the subgroup of 93 pts who received subsequent Immune Checkpoint Inhibitors (ICI), mOS was not reached ..
So Peregrine hires Epiontis and Precision For Medicine
What do you think Sven learned from the IP held by Peregrine and in phase III Sunrise trial ? Looks like Sven learning the correct order of operations and it includes PS TARGETING because you think the laast patents filed by Sven just appeared out of great luck? No way and pay attention to "..identification of immune cells.." aka Sunrise analysis of Biomarkers would likely help the latest patents filed by Sven
Chris joined Berkshire Partners in 1998 and became a Managing Director in 2006. Prior to Berkshire, Chris worked at Bain & Co. Earlier in his career, he worked as a consultant to the consumer products industry. Chris is a Trustee of Dana-Farber Cancer Institute." http://m.berkshirepartners.com/bio_hadley
"“Precision has built a unique and compelling set of services that address the most important challenges facing biopharmaceutical and diagnostic companies,” said Chris Hadley, a Managing Director at Berkshire Partners. “We are thrilled to participate in the next leg of growth and expansion focused on accelerating development and demonstrating value for customers.” https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137341358
Market Data 
Markets 
AI
